<DOC>
	<DOCNO>NCT00962624</DOCNO>
	<brief_summary>The study involve measurement immune response vaccination three dose meningococcal B vaccine single dose meningococcal ACYW conjugate vaccine healthy adult ( Laboratory worker ) . The study complete Manchester Medical Microbiology Partnership UK enrol staff may potential occupational exposure meningococci . Blood sample take vaccination use determine vaccine induce protective response .</brief_summary>
	<brief_title>Study Meningococcal B Vaccine ACWY Conjugate Vaccine Healthy Adults</brief_title>
	<detailed_description>Laboratory staff Manchester Medical Microbiology Partnership may potential occupational exposure meningococci . No licensed vaccine available serogroup B meningococci available plain polysaccharide serogroup ACYW vaccine poorly immunogenic . Novartis Vaccines develop investigational serogroup B vaccine conjugate ACYW vaccine . This study investigate vaccine ability induce protective response laboratory staff Manchester Medical Microbiology Partnership . Three dose meningococcal B vaccine administer 0 , 2 6 month single dose administer 0 month . Blood sample take vaccination functional antibody determine .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 1865 year age Who give write informed consent nature study explain . Who work within Manchester Medical Microbiology Partnership may potential occupational exposure meningococci . The possibility pregnancy A serious chronic disease include progressive neurological disease seizure disorder . Have know bleeding diathesis , condition may associate prolonged bleeding time . Have history severe allergic reaction previous vaccination anaphylactic shock , asthma , urticaria , allergic reaction hypersensitivity vaccine component . Have receive another investigational agent within 90 day completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another investigational trial end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Meningitis</keyword>
</DOC>